Lack of association between MTHFR Ala222Val and Glu429Ala polymorphisms and bladder cancer risk: A meta‑analysis of case‑control studies

Shi,Rong; Zhao,Zhen; Zhou,Hui; Zhou,Jueyu; Tan,Wanlong

doi:10.3892/br.2014.258

Lack of association between MTHFR Ala222Val and Glu429Ala polymorphisms and bladder cancer risk: A meta‑analysis of case‑control studies

Authors:
- Rong Shi
- Zhen Zhao
- Hui Zhou
- Jueyu Zhou
- Wanlong Tan
View Affiliations

Affiliations: Institute of Genetic Engineering, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, Department of Urinary Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
Published online on: March 19, 2014 https://doi.org/10.3892/br.2014.258
Pages: 396-403

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bladder cancer is a commom malignancy in the urinary tract that is influenced by genetic and environmental factors. The role of functional polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene with bladder cancer risk remains to be determined. This meta‑analysis was performed to derive a more precise estimation of MTHFR Ala222Val and Glu429Ala polymorphisms and bladder cancer risk. Data were collected with the last report up to September 2013. A total of 3,463 cases and 3,927 controls for Ala222Val, and 3,177 cases and 3,502 controls for Glu429Ala were analyzed. The pooled odds ratios (ORs) and 95% confidence interval (CI) were estimated for the association with bladder cancer risk. Overall, no significant associations of Ala222Val and Glu429Ala polymorphisms with bladder cancer risk were found (for Ala222Val: Val/Val vs. Ala/Ala: OR, 1.02; 95% CI: 0.80‑1.29; Val/Ala vs. Ala/Ala: OR, 1.02; 95% CI: 0.92‑1.12; dominant model: OR, 1.01; 95% CI: 0.87‑1.17; recessive model: OR, 1.00; 95% CI: 0.87‑1.15; and for Glu429Ala: Ala/Ala vs. Glu/Glu: OR, 1.11; 95% CI: 0.78‑1.58; Ala/Glu vs. Glu/Glu: OR, 1.16; 95% CI: 0.95‑1.40; dominant model: OR, 1.15; 95% CI: 0.94‑1.41; recessive model: OR, 0.96; 95% CI: 0.79‑1.15). In stratiﬁed analyses by ethnicity, signiﬁcant associations were observed for Glu429Ala polymorphism in individuals of Middle Eastern descent (Ala/Glu vs. Glu/Glu: OR, 2.11; 95% CI: 1.26‑3.53; dominant model: OR, 2.16; 95% CI: 1.16‑4.01; recessive model: OR, 1.82; 95% CI: 1.11‑3.01). This meta‑analysis demonstrated that overall there was no association of MTHFR Ala222Val and Glu429Ala polymorphisms with bladder cancer risk. However, in the stratified analysis by ethnicity the MTHFR Glu429Ala polymorphism was signiﬁcantly associated with increased bladder cancer risk in individuals of Middle Eastern descent.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Ploeg M, Aben KK and Kiemeney LA: The present and future burden of urinary bladder cancer in the world. World J Urol. 27:289–293. 2009. View Article : Google Scholar : PubMed/NCBI
3	Chu H, Wang M and Zhang Z: Bladder cancer epidemiology and genetic susceptibility. J Biomed Res. 27:170–178. 2013. View Article : Google Scholar
4	Cordon-Cardo C: Molecular alterations associated with bladder cancer initiation and progression. Scand J Urol Nephrol Suppl. 154–165. 2008. View Article : Google Scholar : PubMed/NCBI
5	Lin J, Spitz MR, Wang Y, et al: Polymorphisms of folate metabolic genes and susceptibility to bladder cancer: a case-control study. Carcinogenesis. 25:1639–1647. 2004. View Article : Google Scholar : PubMed/NCBI
6	Rouissi K, Ouerhani S, Oliveira E, et al: Polymorphisms in one-carbon metabolism pathway genes and risk for bladder cancer in a Tunisian population. Cancer Genet Cytogenet. 195:43–53. 2009. View Article : Google Scholar : PubMed/NCBI
7	Moore LE, Malats N, Rothman N, et al: Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer. Int J Cancer. 120:2452–2458. 2007. View Article : Google Scholar : PubMed/NCBI
8	Bailey LB: Folate, methyl-related nutrients, alcohol, and the MTHFR 677C→T polymorphism affect cancer risk: intake recommendations. J Nutr. 133(Suppl 1): S3748–S3753. 2003.PubMed/NCBI
9	Frosst P, Blom HJ, Milos R, et al: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 10:111–113. 1995. View Article : Google Scholar : PubMed/NCBI
10	Weisberg I, Tran P, Christensen B, Sibani S and Rozen R: A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab. 64:169–172. 1998. View Article : Google Scholar : PubMed/NCBI
11	Yin G, Kono S, Toyomura K, et al: Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and colorectal cancer: the Fukuoka Colorectal Cancer Study. Cancer Sci. 95:908–913. 2004. View Article : Google Scholar : PubMed/NCBI
12	Tong N, Fang Y, Li J, et al: Methylenetetrahydrofolate reductase polymorphisms, serum methylenetetrahydrofolate reductase levels, and risk of childhood acute lymphoblastic leukemia in a Chinese population. Cancer Sci. 101:782–786. 2010. View Article : Google Scholar
13	Boccia S, Gianfagna F, Persiani R, et al: Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and susceptibility to gastric adenocarcinoma in an Italian population. Biomarkers. 12:635–644. 2007. View Article : Google Scholar : PubMed/NCBI
14	Galbiatti AL, Ruiz MT, Rodrigues JO, et al: Polymorphisms and haplotypes in methylenetetrahydrofolate reductase gene and head and neck squamous cell carcinoma risk. Mol Biol Rep. 39:635–643. 2012. View Article : Google Scholar : PubMed/NCBI
15	Mantel N and Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 22:719–748. 1959.PubMed/NCBI
16	DerSimonian R and Laird N: Meta-analysis in clinical trials. Control Clin Trials. 7:177–188. 1986. View Article : Google Scholar : PubMed/NCBI
17	Egger M, Davey Smith G, Schneider M and Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
18	Kimura F, Florl AR, Steinhoff C, et al: Polymorphic methyl group metabolism genes in patients with transitional cell carcinoma of the urinary bladder. Mutat Res. 458:49–54. 2001.PubMed/NCBI
19	Moore LE, Wiencke JK, Bates MN, Zheng S, Rey OA and Smith AH: Investigation of genetic polymorphisms and smoking in a bladder cancer case-control study in Argentina. Cancer Lett. 211:199–207. 2004. View Article : Google Scholar : PubMed/NCBI
20	Sanyal S, Festa F, Sakano S, et al: Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis. 25:729–734. 2004. View Article : Google Scholar : PubMed/NCBI
21	Karagas MR, Park S, Nelson HH, et al: Methylenetetrahydrofolate reductase (MTHFR) variants and bladder cancer: a population-based case-control study. Int J Hyg Environ Health. 208:321–327. 2005. View Article : Google Scholar : PubMed/NCBI
22	Ouerhani S, Oliveira E, Marrakchi R, et al: Methylenetetrahydrofolate reductase and methionine synthase polymorphisms and risk of bladder cancer in a Tunisian population. Cancer Genet Cytogenet. 176:48–53. 2007. View Article : Google Scholar : PubMed/NCBI
23	Cai DW, Liu XF, Bu RG, et al: Genetic polymorphisms of MTHFR and aberrant promoter hypermethylation of the RASSF1A gene in bladder cancer risk in a Chinese population. J Int Med Res. 37:1882–1889. 2009. View Article : Google Scholar : PubMed/NCBI
24	Ouerhani S, Rouissi K, Marrakchi R, et al: Combined effect of NAT2, MTR and MTHFR genotypes and tobacco on bladder cancer susceptibility in Tunisian population. Cancer Detect Prev. 32:395–402. 2009. View Article : Google Scholar : PubMed/NCBI
25	Wang M, Zhu H, Fu G, Wang M and Zhang Z, Lu Q, Wang S and Zhang Z: Polymorphisms of methylenetetrahydrofolate reductase and methionine synthase genes and bladder cancer risk: a case-control study with meta-analysis. Clin Exp Med. 9:9–19. 2009. View Article : Google Scholar : PubMed/NCBI
26	Chung CJ, Pu YS, Su CT, et al: Polymorphisms in one-carbon metabolism pathway genes, urinary arsenic profile, and urothelial carcinoma. Cancer Causes Control. 21:1605–1613. 2010. View Article : Google Scholar : PubMed/NCBI
27	Safarinejad MR, Shafiei N and Safarinejad S: Genetic susceptibility of methylenetetrahydrofolate reductase (MTHFR) gene C677T, A1298C, and G1793A polymorphisms with risk for bladder transitional cell carcinoma in men. Med Oncol. 28(Suppl 1): S398–S412. 2011. View Article : Google Scholar : PubMed/NCBI
28	Hirschhorn JN, Lohmueller K, Byrne E and Hirschhorn K: A comprehensive review of genetic association studies. Genet Med. 4:45–61. 2002. View Article : Google Scholar : PubMed/NCBI
29	Munafo MR and Flint J: Meta-analysis of genetic association studies. Trends Genet. 20:439–444. 2004. View Article : Google Scholar : PubMed/NCBI